SloveniaThe Slovenian biotechnology company GenePlanet has secured a new investor, Lauxera Capital Partners, a Paris- and San Francisco-based venture capital firm specializing in health technologies. This investment marks a significant milestone in GenePlanet's growth strategy, aiming to expand globally and become a leading provider of advanced diagnostics, personalized medicine, and oncology services. Lauxera brings expertise in diagnostic development, access to Western European and U.S. markets, and a network of industry professionals. The partnership follows partial divestment by BlackPeak Capital, which had been a development partner since 2023 but remains a shareholder. GenePlanet plans to expand its portfolio of genetic tests in oncology and rare diseases while accelerating market entry in high-revenue regions.
Bias read (Center): The article reports on a corporate investment and strategic partnership between a Slovenian biotech firm and a foreign venture capital group. It focuses on business expansion, technological advancement, and market strategies without taking a stance on political issues, policies, or ideological views
